United Kingdom· GB-APID-4004711000001103
Neo-Cortef ear/eye drops
A medicinal product containing hydrocortisone + neomycin, registered in United Kingdom by PLIVA Pharma Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Hydrocortisone + Neomycin
- Manufacturer
- PLIVA Pharma Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Hydrocortisone + neomycin in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1db54bed-54cc-4695-8f15-bf4e938c8d85 GET /v1/drugs/1db54bed-54cc-4695-8f15-bf4e938c8d85?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "4004711000001103",
"desc": "Neo-Cortef ear/eye drops (PLIVA Pharma Ltd)",
"form": "Ear/eye drops solution",
"vpid": "42190911000001106",
"source": "dmd",
"vtm_id": "776254002",
"strength": "15 mg",
"substance": "Hydrocortisone + Neomycin",
"ingredient": "Hydrocortisone acetate",
"supplier_code": "2762101000001104"
}See everything about hydrocortisone + neomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.